Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints

Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.

T cell

The spectacular failureofBristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo in the CheckMate 026 first-line lung cancer study raises questions about whether the right cut-off levels for the PD-L1 expression biomarker were used.

Bristol reported that the drug missed the primary progression-free-survival endpoint in the first-line CheckMate 026 study on Aug. 5, prompting...

More from R&D

Sponsors Asked, EMA Delivered: One Handbook To Navigate CTIS

 
• By 

The European Medicines Agency has revised the sponsor handbook for the Clinical Trials Information System, bringing together guidance that was previously scattered across multiple platforms and documents to help sponsors navigate the trial process more efficiently.

Sarepta Refuses To Stop Elevidys Shipments After Third Death Linked To Gene Therapy Vector

 
• By 

Sarepta knew about the death in a Phase I trial of SRP-9004 for LGMD when it recently revealed a restructuring plan, but did not disclose the event. The now-discontinued gene therapy candidate uses the same AAV vector as Elevidys, which has been linked to two DMD patient deaths.

UK HRA Sets Targets For Digital Overhaul, Trial Transparency And Trust

 
• By 

The UK Health Research Authority’s latest three-year strategy sets ambitious targets to make research more transparent. One World Health Organization official believes the authority can go further by setting equally high standards for the timely reporting of clinical trial results.

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

More from Pink Sheet

Advocates Want New Bipartisan PBM Reform Package To Stand Alone

 
• By 

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By 

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.